Clinica Baviera, SA (ES:CBAV)
BME:CBAV
Want to see ES:CBAV full AI Analyst Report?
CBAV Stock Chart & Stats
€47.30
€0.20(0.61%)
At close: 4:00 PM EST
€47.30
€0.20(0.61%)
Day’s Range― - ―
52-Week Range€37.70 - €58.00
Previous CloseN/A
Volume285.00
Average Volume (3M)2.20K
Market Cap
€919.52M
Enterprise Value€903.06M
Total Cash (Recent Filing)€50.32M
Total Debt (Recent Filing)€69.16M
Price to Earnings (P/E)15.3
Beta0.58
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.31%
Share Statistics
EPS (TTM)2.57
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)€325.40M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue & Earnings GrowthMulti-year top-line and net income growth through 2021–2025 indicates durable demand for ophthalmology services and successful clinic expansion. Sustained revenue trends support long-term cash generation, capacity to reinvest in clinics and technology, and resilience across economic cycles.
Consistent Positive Operating Cash FlowRegularly positive operating cash flow that typically outpaces reported earnings signals strong cash conversion and high earnings quality. This provides lasting funding power for capex, working capital, and shareholder returns without depending heavily on external financing across planning horizons.
Improving Balance Sheet And Strong ReturnsRising equity, reduced leverage versus prior peaks, and strong returns on capital demonstrate improving financial resilience and efficient use of invested capital. These durable balance-sheet gains support strategic investments, potential M&A, and cushioning against cyclical healthcare demand swings.
Bears Say
Debt Trending Up Into 2024–2025A renewed rise in debt levels into 2024–2025 reduces financial flexibility and increases interest and refinancing exposure. If organic growth moderates, higher leverage can constrain capital allocation to expansion, capex or dividends and raises vulnerability to rising rates over the medium term.
Free-cash-flow Volatility; Sharp 2025 DropNotable FCF volatility and a sharp 2025 decline despite solid operating cash flow suggest higher capex or working-capital swings. Persistent FCF variability undermines planning certainty, may force incremental external funding for growth, and limits free funds for dividends or buybacks.
2025 Growth Slowdown And Margin/data NoiseA slowdown in 2025 combined with anomalous 2024 gross-profit presentation clouds assessment of sustainable margins. If parts of prior margin strength were one-offs or accounting artifacts, forward profitability may prove weaker than headline trends imply, complicating medium-term forecasts.
Clinica Baviera News
CBAV FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest stock price was €37.70 and its highest was €58.00 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €919.52M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Jul 28, 2026 which is in 68 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Mar 04, 2026. The company reported €0.813 earnings per share for the quarter, beating the consensus estimate of N/A by €0.813.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Overvalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA pays a Annually dividend of €1.57 which represents an annual dividend yield of 3.31%. See more information on Clinica Baviera, SA dividends here
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.813 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.789%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in ES:CBAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clinica Baviera (CBAV) is a leading provider of ophthalmological services in Spain and several other countries, specializing in vision correction procedures such as LASIK and cataract surgery. The clinic operates a network of medical centers equipped with advanced technology and staffed by highly trained professionals to deliver quality eye care. In addition to surgical interventions, Clinica Baviera offers comprehensive eye examinations, diagnostic services, and post-operative care, focusing on improving patients' quality of life through enhanced vision.
Technical Analysis
Options Prices
Currently, No data available
---